Important advance in TB treatment (opens original article in a new tab)

South African and US researchers developed a new six-month TB treatment regimen that shows similar effectiveness to the nine-month standard treatment, with potential benefits for vulnerable populations.

• Researchers from South Africa and the US published a study in the New England Journal of Medicine on a new six-month TB treatment regimen.
• The new regimen, which includes bedaquiline, linezolid, delamanid, and either levofloxacin or clofazimine, showed 86% success rate in treating rifampicin-resistant TB.
• The study included a diverse population, including people with HIV and pregnant or breastfeeding women, and was conducted in real-world health settings.